vs
太平洋生物科学（ASMB）与礼来（RNA）财务数据对比。点击上方公司名可切换其他公司
礼来的季度营收约是太平洋生物科学的1.2倍（$12.5M vs $10.8M），太平洋生物科学净利率更高（-85.2% vs -1398.3%，领先1313.1%），礼来同比增速更快（434.0% vs 57.6%），太平洋生物科学自由现金流更多（$-15.2M vs $-156.9M）
该公司是一家成立于2004年的美国生物科技企业，主要研发生产基因测序相关设备，同时也开展新型实时生物观测技术相关业务。目前拥有两大核心测序平台，分别是基于零模波导特性的单分子实时测序平台，以及结合天然核苷酸无痕连接技术的结合测序平台。
礼来是总部位于美国印第安纳州印第安纳波利斯的跨国制药企业，在18个国家设有办事处，产品销往全球约125个国家。公司由美国内战时期联邦军退伍军人、药剂师伊莱·礼来于1876年创立，品牌名即取自创始人姓名。
ASMB vs RNA — 直观对比
营收规模更大
RNA
是对方的1.2倍
$10.8M
营收增速更快
RNA
高出376.4%
57.6%
净利率更高
ASMB
高出1313.1%
-1398.3%
自由现金流更多
ASMB
多$141.7M
$-156.9M
损益表 — Q3 FY2025 vs Q3 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $10.8M | $12.5M |
| 净利润 | $-9.2M | $-174.4M |
| 毛利率 | — | — |
| 营业利润率 | -100.9% | -1513.5% |
| 净利率 | -85.2% | -1398.3% |
| 营收同比 | 57.6% | 434.0% |
| 净利润同比 | 4.3% | -117.0% |
| 每股收益（稀释后） | $-0.72 | $-1.27 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收ASMBRNA
| Q3 25 | $10.8M | $12.5M | ||
| Q2 25 | $9.6M | $3.8M | ||
| Q1 25 | $9.4M | $1.6M | ||
| Q4 24 | $7.4M | $3.0M | ||
| Q3 24 | $6.8M | $2.3M | ||
| Q2 24 | $8.5M | $2.0M | ||
| Q1 24 | $5.8M | $3.5M | ||
| Q4 23 | — | $2.2M |
净利润ASMBRNA
| Q3 25 | $-9.2M | $-174.4M | ||
| Q2 25 | $-10.2M | $-157.3M | ||
| Q1 25 | $-8.8M | $-115.8M | ||
| Q4 24 | — | $-102.3M | ||
| Q3 24 | $-9.6M | $-80.4M | ||
| Q2 24 | $-11.2M | $-70.8M | ||
| Q1 24 | $-9.1M | $-68.9M | ||
| Q4 23 | — | $-60.4M |
营业利润率ASMBRNA
| Q3 25 | -100.9% | -1513.5% | ||
| Q2 25 | -115.2% | -4448.7% | ||
| Q1 25 | -105.5% | -8360.9% | ||
| Q4 24 | — | -4069.6% | ||
| Q3 24 | -160.1% | -4200.9% | ||
| Q2 24 | -143.0% | -4040.4% | ||
| Q1 24 | -185.5% | -2178.6% | ||
| Q4 23 | — | -3043.5% |
净利率ASMBRNA
| Q3 25 | -85.2% | -1398.3% | ||
| Q2 25 | -105.9% | -4089.3% | ||
| Q1 25 | -93.6% | -7360.0% | ||
| Q4 24 | — | -3439.5% | ||
| Q3 24 | -140.4% | -3441.7% | ||
| Q2 24 | -130.7% | -3461.8% | ||
| Q1 24 | -156.9% | -1943.4% | ||
| Q4 23 | — | -2756.2% |
每股收益（稀释后）ASMBRNA
| Q3 25 | $-0.72 | $-1.27 | ||
| Q2 25 | $-1.33 | $-1.21 | ||
| Q1 25 | $-1.17 | $-0.90 | ||
| Q4 24 | — | $-0.80 | ||
| Q3 24 | $-1.51 | $-0.65 | ||
| Q2 24 | $-1.98 | $-0.65 | ||
| Q1 24 | $-1.66 | $-0.79 | ||
| Q4 23 | — | $-0.80 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $22.5M | $350.2M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $182.7M | $1.9B |
| 总资产 | $240.0M | $2.1B |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资ASMBRNA
| Q3 25 | $22.5M | $350.2M | ||
| Q2 25 | $24.0M | $243.9M | ||
| Q1 25 | $23.4M | $254.2M | ||
| Q4 24 | $38.3M | $219.9M | ||
| Q3 24 | $28.5M | $370.2M | ||
| Q2 24 | $19.2M | $575.8M | ||
| Q1 24 | $18.7M | $471.4M | ||
| Q4 23 | — | $185.1M |
股东权益ASMBRNA
| Q3 25 | $182.7M | $1.9B | ||
| Q2 25 | $18.1M | $1.2B | ||
| Q1 25 | $27.1M | $1.3B | ||
| Q4 24 | $33.4M | $1.4B | ||
| Q3 24 | $26.0M | $1.5B | ||
| Q2 24 | $34.7M | $1.2B | ||
| Q1 24 | $32.6M | $830.9M | ||
| Q4 23 | — | $500.8M |
总资产ASMBRNA
| Q3 25 | $240.0M | $2.1B | ||
| Q2 25 | $80.8M | $1.4B | ||
| Q1 25 | $99.0M | $1.5B | ||
| Q4 24 | $119.2M | $1.6B | ||
| Q3 24 | $100.3M | $1.6B | ||
| Q2 24 | $115.3M | $1.3B | ||
| Q1 24 | $119.9M | $951.5M | ||
| Q4 23 | — | $628.6M |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-15.1M | $-156.2M |
| 自由现金流经营现金流 - 资本支出 | $-15.2M | $-156.9M |
| 自由现金流率自由现金流/营收 | -140.7% | -1257.6% |
| 资本支出强度资本支出/营收 | 0.4% | 5.7% |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | — | $-592.3M |
8季度趋势，按日历期对齐
经营现金流ASMBRNA
| Q3 25 | $-15.1M | $-156.2M | ||
| Q2 25 | $-16.8M | $-199.7M | ||
| Q1 25 | $-23.4M | $-124.8M | ||
| Q4 24 | $-51.1M | $-99.9M | ||
| Q3 24 | $-15.2M | $-65.6M | ||
| Q2 24 | $-17.1M | $-65.0M | ||
| Q1 24 | $-18.4M | $-70.4M | ||
| Q4 23 | — | $16.5M |
自由现金流ASMBRNA
| Q3 25 | $-15.2M | $-156.9M | ||
| Q2 25 | — | $-203.0M | ||
| Q1 25 | — | $-128.6M | ||
| Q4 24 | $-51.1M | $-103.8M | ||
| Q3 24 | — | $-67.3M | ||
| Q2 24 | $-17.1M | $-65.5M | ||
| Q1 24 | $-18.4M | $-71.3M | ||
| Q4 23 | — | $15.6M |
自由现金流率ASMBRNA
| Q3 25 | -140.7% | -1257.6% | ||
| Q2 25 | — | -5277.1% | ||
| Q1 25 | — | -8174.3% | ||
| Q4 24 | -695.2% | -3491.0% | ||
| Q3 24 | — | -2881.8% | ||
| Q2 24 | -200.6% | -3204.6% | ||
| Q1 24 | -317.7% | -2012.3% | ||
| Q4 23 | — | 713.1% |
资本支出强度ASMBRNA
| Q3 25 | 0.4% | 5.7% | ||
| Q2 25 | 0.0% | 86.9% | ||
| Q1 25 | 0.0% | 238.6% | ||
| Q4 24 | 0.4% | 131.7% | ||
| Q3 24 | 0.0% | 72.9% | ||
| Q2 24 | 0.2% | 26.0% | ||
| Q1 24 | 0.2% | 25.8% | ||
| Q4 23 | — | 39.4% |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
